The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...

The liver, a crucial organ, faces stress from toxins and poor lifestyle choices, leading to potential dysfunction. Early ...

With significant hedge fund interest and a share price under $10, 89bio, Inc. (NASDAQ:ETNB) secures a spot on our list of the ...

The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...

Prosecutors charged Blair Hamilton Hayes, 61 with causing the death of 47-year-old Emma Jean Teague this March ...

Novo Nordisk’s stock popped Monday after it announced a cash discount for uninsured Ozempic users and gained FDA approval for ...

A man accused of leaving a “fragile” woman in an unheated camper during the winter is at fault in her cold-related death, ...

A Vietnamese study of cirrhotic patients with esophageal variceal bleeding finds no significant difference in outcomes ...

Liver failure syndromes are characterized by a dysregulated immune response leading to immune paralysis. Adrenomedullin (ADM) ...

USA: A recent study published in Diabetes, Obesity and Metabolism has reported that the use of glucagon-like peptide-1 ...

The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...